High deductibles, rising coinsurance, and increasingly sophisticated payer cost-management tactics have turned affordability into the silent gatekeeper between being prescribed a treatment and starting it. In other words, patients filling medications are increasingly responsible for thousands of dollars in out-of-pocket costs, a reality that often leads to treatment abandonment.

As manufacturers have responded with generous copay assistance programs, payers have countered with accumulators and maximizers, two techniques designed to pull maximum value from copay assistance programs.

Accumulator programs prevent manufacturer copay assistance from counting toward a patient’s deductible or out-of-pocket maximum. So, when copay support runs out mid-year, the patient faces unexpected bills, popularly referred to as a copay surprise. For some patients, this leads to an unexpected discontinuation of therapy due to these new costs. Meanwhile, maximizers adjust patient cost-sharing to extract the full value of manufacturer support—with program administrators often charging fees of up to 25% or more of a copay program’s value.

For emerging biopharma companies (EBPs), this is where the promise of innovation often encounters the hard reality of healthcare economics. As payer tactics add “fat” into the system, EBPs need to plan strategically upfront to mitigate their impact rather than reacting after implementation. In short, patient affordability programs are a commercialization imperative. But without a proactive, data-informed strategy, you could overspend on affordability programs while still failing to prevent patient drop-off.

Start with strategy, not spending

Before designing a patient support structure, address the following questions:

• What payer tactics will your patients encounter?
• What out-of-pocket costs will different patient segments face?
• How do patients in your therapeutic area respond to high costs?
• What support helps your patients overcome barriers?

With answers to these questions, along with insights from claims data and benefits verification for similar products, you can begin to map your patients’ access journey, quantify accumulator and maximizer prevalence, and anticipate barriers. As importantly, assess patient cost sensitivity, recognizing that a $50 copay might be trivial in oncology but a dealbreaker for someone managing a chronic condition.

Then segment your approach, given that all patients won’t need the same support. Clarify benefit designs, accumulator exposure, and maximizer risk, and explore the potential for alternative funding scenarios. Tailor your tactics and benefit levels accordingly to avoid both overspending on some patients and underserving others.

Think ahead to protect patients and budgets

When managing the impact of accumulators and maximizers, adopting a “wait-and-see” approach can be a losing proposition, quickly impacting overall gross to net for your product. For example, if a company discovers accumulator exposure only after patients fill multiple claims through traditional copay cards, they’ve already surrendered benefit value that should have counted toward patients’ out-of-pocket responsibility. Or, perhaps an organization builds a patient support budget that assumes 15% accumulator exposure. When they discover that actual exposure is 35%, they’re forced to make disruptive mid-year changes. These changes can elevate the risk that patients will drop off therapy.

Instead of making assumptions, use benefit verification data combined with adjudication patterns to identify at-risk patients at first touch. The sooner you flag these patients, the more options you have to route them to appropriate payment mechanisms without delaying therapy. Also, explore the value of smart funding mechanisms, such as patient debit cards funded by the manufacturer. These affordability tools reduce accumulator exposure while creating auditable trails. They function as patient-controlled funds that pharmacies are less likely to reject as manufacturer assistance.

Meanwhile, benefit design levers let you fine-tune spending with tiered caps that vary by patient risk profile, dynamic lookback periods, pharmacy-level business rules, and geography-specific adjustments. Set higher caps for traditional plans where patients genuinely need substantial assistance, and more conservative caps for maximizer patients where unlimited support simply enriches payers rather than benefits your patient.

Payer tactics evolve annually as new accumulators emerge, maximizer administrators refine approaches, and benefit designs shift. With that in mind, plan on annual optimization reviews to keep your program effective.

Strategic focus matters more than budget size

Without deliberately designed patient support, even breakthrough therapies struggle when patients abandon treatment due to cost. Fortunately, it’s a myth that strategic affordability requires “Big Pharma” budgets. What it takes is diagnostic insight into where your patients face friction, as well as strategic focus on the interventions with highest leverage.

Invest in developing and designing the right patient support program right from the start, with analytics that surface real patient dynamics, benefit designs that match segment needs, funding mechanisms that mitigate payer tactics, and governance infrastructure that protects both the integrity and the impact of your patient support efforts.

Best-in-class programs achieve proactive patient identification, deploy dynamic benefit caps by segment, and maintain governed, auditable rules. They also incorporate patient and provider education on how to frame the support to pharmacies to reduce friction. Using this approach, IQVIA has helped pharmaceutical organizations design and redesign integrated patient support that has improved abandonment rates, lifted approved fills, and increased fills completed within 14 days.

Whether you are an EBP preparing for launch or seeking to optimize existing patient support, consider reaching out to IQVIA. By orchestrating industry-leading data assets, market access expertise, and operational capabilities, we help EBPs build affordability programs that protect patient access while delivering measurable commercial outcomes. Learn more at Emerging Biopharma and Biotech - IQVIA.